Kooij Louise Frederika — SEC Form 4 filings
SEC reporting owner CIK 2004379. 16 Form 4 filings on record with FilingPulse; latest filed 2026-07-22.
Transaction summary — filings shown
Covers all 16 filings on record, filed 2024-10-01 to 2026-07-22. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 22 legs across 12 filings — 873,989 shares, $25,046,057 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 43.
- Largest priced transaction: sale of 150,000 shares @ $20.37 ($3,055,500) in NewAmsterdam Pharma Co N.V., filed 2025-03-05.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | Chief Accounting Officer | 16 | — | 22 legs · 873,989 sh · $25,046,057 | 43 |
Form 4 filings — Kooij Louise Frederika
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-22 | 4 | NewAmsterdam Pharma Co N.V. (NAMS) | Option exercise (M): 25,000 @ $11.90 · Option exercise (M): 80,000 @ $11.17 · Sale (S): 70,200 @ $29.96 · Sale (S): 31,885 @ $31.05 · Sale (S): 2,915 @ $31.71 · Option exercise (M): 25,000 (derivative) @ $0 · +1 more | EDGAR |
| 2026-06-24 | 4 | NewAmsterdam Pharma Co N.V. (NAMS) | Option exercise (M): 25,000 @ $10.90 · Option exercise (M): 15,000 @ $11.90 · Sale (S): 39,700 @ $30.20 · Sale (S): 300 @ $30.73 · Option exercise (M): 25,000 (derivative) @ $0 · Option exercise (M): 15,000 (derivative) @ $0 | EDGAR |
| 2026-05-27 | 4 | NewAmsterdam Pharma Co N.V. (NAMS) | Option exercise (M): 60,000 @ $10 · Option exercise (M): 5,000 @ $10.90 · Sale (S): 65,000 @ $35.69 · Option exercise (M): 60,000 (derivative) @ $0 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2026-01-29 | 4 | NewAmsterdam Pharma Co N.V. (NAMS) | Option exercise (M): 39,816 @ $10.90 · Sale (S): 39,816 @ $32.62 · Option exercise (M): 32,612 @ $10.90 · Sale (S): 32,612 @ $31.80 · Option exercise (M): 39,816 (derivative) @ $0 · Option exercise (M): 32,612 (derivative) @ $0 | EDGAR |
| 2026-01-27 | 4 | NewAmsterdam Pharma Co N.V. (NAMS) | Option exercise (M): 38,172 @ $10.90 · Sale (S): 25,405 @ $33.44 · Sale (S): 12,767 @ $34.37 · Option exercise (M): 34,400 @ $10.90 · Sale (S): 34,091 @ $32.77 · Sale (S): 309 @ $33.45 · +2 more | EDGAR |
| 2026-01-07 | 4 | NewAmsterdam Pharma Co N.V. (NAMS) | Sale (S): 2,647 @ $33.25 · Grant/award (A): 12,000 · Grant/award (A): 53,500 (derivative) @ $0 | EDGAR |
| 2025-12-29 | 4 | NewAmsterdam Pharma Co N.V. (NAMS) | Option exercise (M): 75,117 @ $10 · Sale (S): 75,117 @ $36.21 · Option exercise (M): 26,011 @ $10 · Sale (S): 26,011 @ $35.68 · Option exercise (M): 38,872 @ $10 · Option exercise (M): 5,000 @ $10.90 · +5 more | EDGAR |
| 2025-09-10 | 4 | NewAmsterdam Pharma Co N.V. (NAMS) | Option exercise (M): 150,000 @ $10 · Sale (S): 53,104 @ $25.31 · Sale (S): 96,896 @ $26.11 · Option exercise (M): 150,000 (derivative) @ $0 | EDGAR |
| 2025-09-05 | 4 | NewAmsterdam Pharma Co N.V. (NAMS) | Sale (S): 18,073 @ $25.09 | EDGAR |
| 2025-09-04 | 4 | NewAmsterdam Pharma Co N.V. (NAMS) | Option exercise (M): 18,073 · Option exercise (M): 18,073 (derivative) @ $0 | EDGAR |
| 2025-08-27 | 4 | NewAmsterdam Pharma Co N.V. (NAMS) | Sale (S): 8,269 @ $24.86 | EDGAR |
| 2025-03-28 | 4 | NewAmsterdam Pharma Co N.V. (NAMS) | Option exercise (M): 8,269 @ $0 · Grant/award (A): 8,269 (derivative) · Option exercise (M): 8,269 (derivative) | EDGAR |
| 2025-03-05 | 4 | NewAmsterdam Pharma Co N.V. (NAMS) | Option exercise (M): 150,000 · Sale (S): 150,000 @ $20.37 · Option exercise (M): 150,000 (derivative) @ $0 | EDGAR |
| 2025-01-07 | 4 | NewAmsterdam Pharma Co N.V. (NAMS) | Grant/award (A): 15,000 | EDGAR |
| 2025-01-06 | 4 | NewAmsterdam Pharma Co N.V. (NAMS) | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2024-10-01 | 4 | NewAmsterdam Pharma Co N.V. (NAMS) | Option exercise (M): 45,000 · Sale (S): 45,000 @ $15.72 · Option exercise (M): 45,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=2004379 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →